At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 442 enrolled
Drug / intervention
Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg +1 moredrug
Likely dose
Symbicort Turbuhaler (budesonide/formoterol) 320/9 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.
In Brief
A Phase 4 clinical trial evaluating Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg and Seretide Diskus (salmeterol/fluticasone) 50/500 μg for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 442 participants across 59 sites in 9 countries.
Detailed Summary
This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Brazil, Denmark, Germany, India, Philippines, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedOct 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedOct 12, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.7 years ago
Interventions
Symbicort Turbuhaler (budesonide/formoterol) 320/9 μgdrug
Seretide Diskus (salmeterol/fluticasone) 50/500 μgdrug